CG Oncology Says Its Bladder Cancer Treatment Cut the Risk of Tumors Returning by 68%

CG Oncology said Nov. 16, 2026, that its phase 3 PIVOT-006 trial of cretostimogene, a treatment delivered into the bladder after a tumor has been surgically removed, met its main goal: patients who received it had a 68% lower risk of the cancer coming back than patients in the trial's control group. The figures are the company's own topline readout, and they have not been published or peer reviewed.
The trial covered people with intermediate-risk and high-grade Ta bladder cancer, tumors that sit in the bladder's lining, after surgeons had cut the tumor out. According to the company's filing with the Securities and Exchange Commission, no treatment has been approved by the U.S. Food and Drug Administration for use after that surgery to keep the cancer from returning in this group of patients.
The company reported a median follow-up of 17 months as of a data cutoff on Oct. 26, 2026, and called the improvement over the control group statistically significant. It also recorded no severe side effects linked to the treatment and no patient stopping treatment because of one.
The company's press-release title calls the improvement "unprecedented." That assessment is the company's, and so are the numbers: the filing's own cautionary language says the topline data rest on a preliminary analysis that may change after a fuller review of the trial, and that the FDA may not agree with how the company reads the results. No independent analysis has been published.
CG Oncology said it now plans to ask the FDA to approve cretostimogene for this group of patients in the second quarter of 2027.
Sources
Medical Disclaimer: This content is provided for general informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition, concern, symptom, or treatment decision.
